Resa Schlossberg

Resa Schlossberg is head of Skadden’s intellectual property and technology transactions practice. She advises clients in numerous industries on a wide range of IP-related issues, focusing on life sciences and technology intensive representations. Her knowledge of molecular biophysics and biochemistry and research experience allow her to understand the scientific and technical aspects of matters.

Ms. Schlossberg structures, drafts, negotiates and advises on joint ventures, strategic alliances, mergers and acquisitions, and agreements such as license, research and development (R&D), collaboration, co-marketing and co-promotion, manufacturing and supply, R&D funding, synthetic royalty deals and consulting. She also conducts IP diligence and evaluates technologies for clients, including pharmaceutical, chemical, biotechnology, cosmetic, medical device and renewable energy companies, among others.

In addition to transactional work, Ms. Schlossberg has significant experience litigating patent infringement disputes in U.S. federal court, representing clients in false advertising and consumer deception matters and counseling on various strategic IP issues. She is a registered patent attorney with the U.S. Patent and Trademark Office.

Ms. Schlossberg was named one of the Top 250 Women in IP and a Transactions Star by Managing IP, 
recognized among LMG Life Sciences’ top practitioners for Licensing & Collaboration and Mergers & 
Acquisitions, and selected to Intellectual Asset Management’s IAM Patent 1000, where she is described as a “master at executing a deep dive into target and competitor portfolios, formulating strategies, structuring deals and successfully negotiating them.” She has also been named one of Lawdragon’s 500 Leading Lawyers in America, 500 Leading Global IP Lawyers and 500 Leading Dealmakers in America.

• Resa was lead IP counsel to TTAM Research Institute in its
  $305 million acquisition of substantially all of 23andMe
  Holding Co.'s assets. This transaction involved the carve-out
  and transfer of a broad array of assets, including genomics
  data, digital health platforms, proprietary algorithms, brand
  assets and research infrastructure. Given the scope of the
  technology assets and the strategic importance of genomic
  and digital health IP, the transaction required careful navigation
  of complex IP, data and privacy intersections to support
  post-closing execution.
• Resa is advising diagnostics company Exact Sciences on the
  intellectual property aspects of its $23 billion acquisition by
  Abbott Laboratories. Announced in November 2025, this
  transaction combines Exact Sciences’ industry-leading cancer
  screening and diagnostic products—including the Cologuard®
  and Oncotype DX® tests, as well as advanced liquid biopsy
  technologies—with Abbott’s global scale and innovation,
  positioning the combined company to accelerate innovation,
  expand access, and transform cancer care for millions of
  patients. Unanimously approved by both boards and expected
  to close in Q2 2026, the deal stands out as a landmark
  “megadeal” in the life sciences sector as the largest health
  care deal in 2025 and the largest deal in the diagnostics sector
  ever.
• Resa counseled International Flavors & Fragrances Inc. (“IFF”)
  in the $2.85 billion sale of its pharma solutions business unit to
  Roquette Frères S.A. (France) and the sale of its nitrocellulose
  business, associated production facilities and the Walsrode
  Industrial Park in Germany to Czechoslovak Group A.S. (Czech
  Republic). Working closely with the IP team and broader deal
  counsel, she was responsible for structuring and advising on
  the allocation and transfer of intellectual property rights in both
  transactions. This included: identifying and segregating the IP
  assets to be transferred with each business unit, including
  patents, know-how, trademarks, and related technology;
  advising on transitional IP arrangements and ongoing use
  rights for retained and divested businesses; and negotiating IP
  provisions across the transaction documents to ensure clarity
  around ownership, licensing, and operational continuity. These
  carve-out transactions required close attention to the
  operational integration of IP with physical sites and supply
  chains, ensuring smooth separation while protecting IFF’s
  retained businesses.
• Resa was co-lead intellectual property counsel to Holcim Ltd.
  in connection with the $30 billion spin-off and U.S. public
  listing of its North American business, Amrize. This complex,
  cross-border transaction separated Holcim’s U.S. and Canadian
  operations into a standalone entity, requiring a comprehensive
  carve-out of all business-critical assets, including intellectual
  property. As co-lead IP counsel, she oversaw: managing the
  identification, separation, and transfer of IP assets — including
  trademarks, patents, know-how, and data — supporting
  Amrize’s operations across the U.S. and Canada; advising on IP
  structuring and intercompany licensing arrangements to
  support both the spun-off entity and Holcim’s retained global
  business; drafting and negotiating IP-related provisions in the
  separation agreement, ancillary commercial agreements, and
  transition services arrangements; and coordinating closely with
  cross-functional and cross-border teams to align IP, branding,
  and regulatory strategy for the newly listed company. Given the
  scale of the spin-off and the brand and technology assets
  involved, the IP workstream was essential to enabling Amrize’s
  independent operations and public market readiness.
• Resa is leading Skadden’s counsel to Lyell Immunopharma, Inc.
  in connection with its exclusive out license from Innovative
  Cellular Therapeutics, Inc. for global (ex-China) rights to ICT's
  colorectal cancer program for up to $915 million. The
  transaction, which was announced in November 2025, will fund
  future data and progress updates from the ronde-cel clinical
  program for cancer patients with large B-cell lymphoma and
  data from the Phase 1 clinical trial of LYL273, a CAR T-cell
  product candidate for the treatment of GCC-expressing
  cancers.

• J.D. (Harlan Fiske Stone Scholar), Columbia Law School
• B.S., Molecular Biophysics and Biochemistry, 

• New York
• U.S. Patent and Trademark Office